Decollogne S, Bertrand I B, Ascensio M, Drubaix I, Lelièvre L G
Laboratoire de Pharmacologie des Transports Ioniques Membranaires, Université Paris 7, France.
J Cardiovasc Pharmacol. 1993;22 Suppl 2:S96-8.
Different isoforms of the (Na+ + K+)-ATPase are expressed in different cell types in which they contribute to specialized properties. Their biochemistry and physiology are complex. These isozymes vary in their sensitivity to cardiac glycosides and to intracellular Na+ and Ca2+ concentrations. Their functional expression at the membrane level in the different parts of kidney, heart, and brain varies with species and during ontogenesis. In rat heart, at birth and postpartum, there are quantitative and qualitative changes in the expression of the (Na+ + K+)-ATPase and Na+/Ca2+ exchange isoforms. The (Na+ + K+)-ATPase isozymes react differently to hormonal regulation and to physiopathological alterations, i.e., cardiac ischemia and cardiac hypertrophy. Considering the diversity of the (Na+ + K+)-ATPase isoforms and their numerous regulations, what could be the targets of endogenous (Na+ + K+)-ATPase inhibitors?
（Na⁺ + K⁺）-ATP酶的不同同工型在不同细胞类型中表达，它们赋予细胞特殊的性质。其生物化学和生理学特性很复杂。这些同工酶对强心苷以及细胞内Na⁺和Ca²⁺浓度的敏感性各不相同。它们在肾脏、心脏和大脑不同部位的膜水平上的功能表达随物种和个体发育过程而变化。在大鼠心脏中，出生时和产后，（Na⁺ + K⁺）-ATP酶和Na⁺/Ca²⁺交换同工型的表达存在数量和质量上的变化。（Na⁺ + K⁺）-ATP酶同工型对激素调节和生理病理改变（即心脏缺血和心脏肥大）的反应不同。考虑到（Na⁺ + K⁺）-ATP酶同工型的多样性及其众多调节方式，内源性（Na⁺ + K⁺）-ATP酶抑制剂的作用靶点可能是什么？
